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Several reports have shown a fast and efficient translocation of TAT-modified lipoplexes and particles into the cell cytoplasm. However, neither
the uptake mechanism nor the biological effect of TAT-modified lipoplexes has been studied in detail. In this report we show that the increase in
gene transfer of TAT-modified lipoplexes depends on the amount of cationic lipid in the lipoplexes and on the way TAT was coupled to the
lipoplexes. We demonstrate that the cellular uptake of both TAT-modified and unmodified lipoplexes is very fast and, in contrast to previous
publications, temperature-dependent. Additionally, after internalization TAT-modified as well as unmodified lipoplexes end up in lysosomal
vesicles, indicating the involvement of clathrin-mediated endocytosis. Furthermore, chlorpromazine, a specific inhibitor of clathrin-dependent
endocytosis, strongly inhibits the cellular uptake and biological activity of both the TAT-modified and unmodified lipoplexes. We also found that
the uptake and biological activity of these lipoplexes are diminished when cholesterol in the cell membrane was bound by filipin, an inhibitor of
the lipid-raft mediated pathway. Considering these data, we conclude that TAT-modified and unmodified lipoplexes are mainly internalized via a
cholesterol-dependent clathrin-mediated pathway.
© 2006 Elsevier B.V. All rights reserved.Keywords: Gene therapy; Endocytosis; Clathrin; Lipid rafts; Lysosome; TAT1. Introduction
Gene therapy may become an important strategy in the
treatment of various diseases. However, the clinical applications
of gene therapy depend largely on the development of suitable
gene transfer vehicles. Although generally not as efficient as
viral vectors, non-viral systems, such as lipids, have the
advantages of being less toxic, safer, non restrictive in DNA
size, potentially targetable, and easy to produce in relatively
large amounts. However, poor transfection efficiencies pre-
sently limit their usefulness for gene therapy applications,
caused by critical steps such as endosomal release and nuclear
uptake [1].⁎ Corresponding authors. Tel.: +32 9 2648047; fax: +32 9 2648189.
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doi:10.1016/j.bbamem.2006.11.006Viruses, such as influenza viruses and adenoviruses, have
developed peptides that warrant their escape from endosomes
by membrane fusion or disruption upon the acidification of the
endosomes. Such viral peptides and also synthetic polymers
capable to disrupt endosomes upon acidification have been
applied to enhance non-viral gene delivery (reviewed by [1–4]).
However, it has been shown that an excessive disruption of
endosomes by endosomolytic agents may be harmful to the cell
[5]. Alternatively, to circumvent the endosomal escape barrier, it
has been proposed to bypass the endosomal pathway by using
cell penetrating peptides (CPPs) that rapidly translocate cargoes
across the cell membrane [6–8]. Peptides derived from the V-1
transactivator of transcription protein or ‘TAT’, have been
shown to facilitate both in vitro and in vivo the intracellular
delivery of cargoes of various sizes and physicochemical
properties (recently reviewed by [8–10]. These TAT peptides,
typically having a positive charge at physiological pH, consist
of a short stretch of basic amino acids (GRKKRRQRRR),
which is responsible for the translocation across cellular mem-
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sequence [11]. Additionally, this sequence also functions as a
nuclear localization signal [12].
Initially it was believed that the uptake of TAT peptide or
TAT peptide conjugated cargoes occurs in a receptor-indepen-
dent [13,14] and temperature-independent manner [11,15–17].
However, this is currently questioned by the increasing
evidence that the original data might originate from artefacts
in the experimental procedure for fixation and removal of
membrane-bound material [18]. Until now, the precise entry
mechanism of TAT peptides and TAT peptide conjugated
cargoes is still controversial (reviewed by [19]). Both clathrin-
mediated endocytosis [20–23], caveolae-mediated endocytosis
[24–27] and macropinocytosis [14,28] have been suggested.
Possibly the mechanism of cellular entry depends on the cell
type, the TAT sequence, physicochemical properties of the
cargo, the amount of TAT peptides on the surface of the cargo,
and the way TAT peptides are bound to the cargo [9].
The ability of TAT peptides to translocate cargoes across cell
membranes is an attractive feature that could bring significant
advantages to the cellular delivery of proteins, therapeutic DNA or
small interfering RNA (siRNA) molecules [24,29,30]. However,
in contrast to TAT peptides conjugated to proteins, the biological
effect and the cellular entry mechanism of TAT/plasmid DNA
(TAT/pDNA) conjugates and in particular TAT-modified lipo-
plexes [30–33] have not been studied in detail. Therefore, in this
work we aimed to determine (1) whether the attachment of TAT
peptides to lipoplexes could enhance their transfection efficiency,
(2) whether the uptake of the TAT-modified lipoplexes is energy
dependent, and (3) the cellular entry mechanism and intracellular
routing of the TAT-modified lipoplexes.
2. Materials and methods
2.1. Materials
Dulbecco's modified Eagle's medium (DMEM), L-glutamine, heat-inacti-
vated fetal bovine serum (FBS), and penicillin–streptomycin were supplied by
GibcoBRL (Merelbeke, Belgium). The TAT peptide AA 37–72 (CFITKALGI-
SYGRKKRRQRRRAPQGSQTHQVSLSKQ) was obtained from the Centra-
lised Facility for AIDS Reagents, EU Programme EVA (European Vaccine
Against AIDS). The secreted alkaline phosphatase (SEAP) expression plasmid
(pMet7 hβc SEAP) was a kind gift from Prof. Tavernier (Ghent University,
Belgium). 1,2-Dioleolyl-3-trimethylammonium-propane (chloride salt)
(DOTAP), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) and 1,2-
distearoyl-sn-glycero-3-phosphatidylethanolamine-N-[maleimide(polyethylene-
glycol)2000] (DSPE-PEG2000-MAL) were purchased from Avanti Polar Lipids
(AL, USA).
2.2. Cell culture
Cos-7 cells (African green monkey kidney cells; ATCC number CRL-1651)
were cultured in Dulbecco's modified Eagle's medium (DMEM) containing
2 mM glutamine, 10% heat-inactivated FBS, 100 U/ml penicillin/streptomycin
and grown at 37 °C in a humidified atmosphere containing 5% CO2.
2.3. Preparation of cationic liposomes
Cationic liposomes composed of DOTAP:DOPE:DSPE-PEG2000-MAL
with molar ratios of 5:5:0.2, 3:7:0.2, and 1:9:0.2 (containing 50 mol%,
30 mol% and 10 mol% DOTAP, respectively) were prepared as describedpreviously [34]. Briefly, appropriate amounts of lipids were dissolved in
chloroform and mixed. To obtain FITC labeled liposomes 0.01 mol% FITC-
DOPE was added to the mixture. The chloroform was subsequently removed
by rotary evaporation at 37 °C followed by flushing the obtained lipid film
with nitrogen during 30 min at room temperature. The dried lipids were then
hydrated by adding HEPES buffer (20 mM, pH 7.4) till a final lipid
concentration of 10.2 mM. After mixing in the presence of glass beads,
liposome formation was allowed overnight at 4C. Thereafter, the formed
liposomes were extruded 11 times through two stacked 100 nm polycarbonate
membrane filters (Whatman, Brentfort, UK) at room temperature using an
Avanti Mini-Extruder (Avanti Polar Lipids).
2.4. Preparation of TAT-modified and unmodified lipoplexes
To prepare ‘post TAT-lipoplexes’, the liposomes, with or without FITC-
DOPE, were mixed with the appropriate amount of pDNA, in a +/− charge ratio
of 4:1 and incubated at room temperature for 30 min. The final concentration of
pDNA in the lipoplex dispersion was 0.126 μg/μl. Subsequently, TAT peptides
were coupled to the MAL-group, present at the end of the PEG chains in DSPE-
PEG2000-MAL. Therefore, the TATAA 37–72 peptide was first incubated under
a nitrogen flow for 2 h with a 10 fold molar excess of TCEP (tris-2
(carboxyethyl)phosphine) to reduce the disulfide bonds. Again under a nitrogen
flow, the ‘activated’ TATAA 37–72 peptide was added to the lipoplexes in a 4
fold molar excess compared to the DSPE-PEG2000-MAL and incubated
overnight at 4 °C on a shaker.
To prepare ‘pre TAT-lipoplexes’, the same protocol was used, except that the
TAT peptide was coupled to the liposomes before they were complexed with the
pDNA.
The unmodified lipoplexes (i.e. lipoplexes without TAT) were prepared as
the ‘pre or post TAT-lipoplexes’, but without the addition of TAT AA 37–72
peptide.
2.5. Size and zeta potential measurements
The average particle size and the zeta potential (ζ) of the liposomes and
lipoplexes were measured by photon correlation spectroscopy (PCS) (Autosizer
4700, Malvern, Worcestershire, UK) and by particle electrophoresis (Zetasizer
2000, Malvern, Worcestershire, UK), respectively. The liposome and lipoplex
dispersions were diluted 40 fold in 20 mM HEPES buffer pH 7.4 before the
particle size and zeta potential were measured.
2.6. Agarose gel electrophoresis
To determine the extent of pDNA association to the liposomes and the
release of the pDNA from the liposomes after incubation with SDS, agarose gel
electrophoresis was used. 18 μl of the TAT-modified and unmodified lipoplexes,
prepared as described above, were mixed with 2 μl 20 μg/μl SDS or 2 μl dH2O
and loaded together with 5 μl 5× loading solution (30% glycerol, 0.02%
bromphenol blue) on a 1% agarose gel prepared in TBE buffer (10.8 g/l Tris
base, 5.5 g/l boric acid and 0.58 g/l EDTA). The samples were subjected to
electrophoresis at 80 V during 45 min and the DNA was visualized by UV
transillumination using ethidium bromide (0.5 μl/ml) staining prior to
photography.
2.7. Cytotoxicity assay
The cytotoxicity of the lipoplexes was determined using the tetrazolium salt
based colorimetric MTTassay (EZ4U, Biomedica, Vienna, Austria) according to
the manufacturer's instructions. Briefly, 2.5×104 cells/cm2 were seeded in a 96-
well plate and allowed to adhere. After 24 h, cells were washed twice with serum
free medium and incubated with lipoplexes, containing 0.18 μg pDNA per cm2
in serum free medium. After 2 h, the complexes were removed and cells were
washed with culture medium. Finally, to each well, 20 μl substrate was added
together with 180 μl culture medium and after 4 h incubation at 37 °C the
concentration of reduced formazan was measured at 450 nm and 630 nm on a
Wallac Victor2 absorbance plate reader (Perkin Elmer-Cetus Life Sciences,
Boston, MA).
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Cells were seeded into 24-well plates (2.5×104 cells/cm2) and allowed to attach
overnight. The culture medium was removed from the cells and they were washed
twice with serum free medium. Subsequently, the lipoplexes (with and without
bound TAT peptide) were diluted in serum free medium and the diluted lipoplexes,
containing 0.18 μg pDNA per cm2, were added to the 24-well plates. Cells were
incubated at 37 °C for 2 h and, after a washing step with culture medium, the
medium was replaced by 1 ml culture medium, and further incubated at 37 °C.
For the transfection experiments at 4 °C the cells, grown overnight as described
above,were cooled down to 4 °Cduring 30min. Subsequently, pre-cooled solutions
for washing and for the transfection were used. After addition of the complexes, the
cells were incubated at 4 °C and after 2 h, cells were washed with culture medium.
For treatment with uptake inhibitors, cells were pre-incubated for 1 h at
37 °C in DMEMwith chlorpromazine (10 mg/ml) [35], filipin III (1 mg/ml) [36]
before the complexes were added. In a recent study we have demonstrated that
these inhibitors, at their respective concentrations, predominately block clathrin
or raft mediated pathways without causing drastic cytotoxic effects [37]. After
removal of the lipoplexes and addition of culture medium, cells were further
incubated in an incubator. After 48 h the SEAP activity in the culture medium
and the total protein concentration in the cells was measured.
2.9. Gene expression analysis
To determine the SEAP activity in the medium, 100 μl of the culture medium
above the cells was taken and incubated at 65 °C for 30min. Subsequently 100 μl
dilution buffer (0.1 M glycine, 1 mMMgCl2, 0.1 mM ZnCl2, pH 10.4) and 15 μl
4-methylumbelliferyl phosphate (4-MUP, 5.1 μg/μl in distilled water) was added
to the culture medium in a 96-well plate. The obtained mixtures were then
incubated at 37 °C and the fluorescence (λex/λem=360/449 nm) was followed
during 45min on aWallac Victor2 fluorescence plate reader (Perkin Elmer-Cetus
Life Sciences, Boston,MA). The fluorescence obtained after 30min was used for
comparing the gene transfer capacity of the different lipoplexes.
Finally, after removing the culture medium, the cells were washed twice with
PBS to remove dead cells and serum proteins. Thereafter, cells were lysed with
lysis buffer (10% glycerol, 2.3% w/v SDS, 0.125 M Tris–HCl, pH 6.8),
sonicated for 30 min and the protein concentration was determined by BioRad
DC protein assay.
2.10. Cell binding and cellular uptake experiments
2.5×104 cells/cm2 were seeded onto sterile glass bottom culture dishes
(MatTek Corporation, MA, USA) and allowed to adhere for 1 day. For lysosome
staining, the cells were incubated during 30 min at 37 °C with 50 pM of the
lysosomal marker LysoTracker® Red (Molecular Probes, Eugene, OR, U.S.A.).
For 4 °C experiments, cells were cooled in the refrigerator during 30 min,
washed with pre-cooled DMEM and incubated with the lipoplexes at 4 °C. At
different time points samples were analyzed.
In the experiments with cellular uptake inhibitors, the cells were pre-
incubated for 1 h at 37 °C in DMEM with chlorpromazine (10 mg/ml) [35],
filipin III (1 mg/ml) [36]. Subsequently, the cells were washed twice with
DMEM before the appropriate amount of fluorescent TAT-modified or
unmodified lipoplexes and inhibitor-containing serum free medium was
added. Immediately after adding lipoplexes, the cells were visualized on
different time points by confocal laser scanning microscopy (CLSM) (BioRad
MRC 1024; Hemel Hempstadt, UK). After capturing the image with a 60× water
immersion objective and a krypton/argon laser (488 nm and 547 nm) for the
excitation of the FITC label and the LysoTracker® Red, pseudocoloring was
performed by using the digital imaging system Confocal Assistant (CAS;
BioRad; Hemel Hempstadt, UK).
2.11. Statistical analysis data
The experimental data in this report (zeta potential, DLS, cytotoxicity and
transfection) are expressed as mean±standard deviation (SD). One way ANOVA
was used to determinewhether data groups differed significantly from each other.
A p-value lower than 0.05 was considered statistically significant.3. Results and discussion
3.1. Preparation and physicochemical characterization of
unmodified and TAT-modified lipoplexes
Pegylated DOTAP:DOPE:DSPE-PEG2000-MAL lipoplexes
bearing covalently bound TAT peptides at the end of their PEG
chains and containing increasing amounts of DOTAP (10, 30
and 50 mol%) were obtained via two strategies: TAT peptides
were either coupled to the PEG chains of the pegylated
liposomes before complexing them with pDNA (‘pre TAT-
lipoplexes’) or after complexing them with pDNA (‘post TAT-
lipoplexes’). The latter approach ensured that the TAT peptides
were presented on the surface of the lipoplexes, a prerequisite for
TAT peptides to promote the internalization of cargoes [38].
Moreover, to prevent that steric hindrance could abolish the
interaction of TATwith the cell membrane [30], we attached the
TAT peptides via a 2 kDa PEG spacer to the lipoplexes by the aid
of DSPE-PEG2000-MAL moieties. The maleimide (MAL)
groups on these PEG chains are known to react specifically
with sulfhydryl groups at neutral pH creating a stable thioether
bond with the N-terminal cysteine of the TAT peptide. A
schematic representation of the TAT-modified lipoplexes is
shown in Fig. 1.
To assess the DNA binding capacity of the cationic liposomes
and the ability of SDS to release the pDNA from the lipoplexes
agarose gel electrophoresis experiments were performed
(Fig. 2). Lipoplexes containing 30 and 50 mol% DOTAP
showed, both in the presence and absence of TAT, a complete
complexation of the pDNA. 10 mol% DOTAP lipoplexes
lacking the TAT peptide failed to bind all the pDNA. Coupling of
TAT peptides to these 10 mol% DOTAP lipoplexes retarded the
pDNA on the agarose gel, but did not result in a full com-
plexation. Finally, the release properties in the presence of SDS
of the different types of lipoplexes were not altered by TAT
peptides.
The effect of the attachment of TAT peptides to the lipoplexes
was further evaluated by comparing the particle size and surface
charge of TAT-modified and unmodified lipoplexes. Fig. 3A and
B show that the attachment of TAT-peptides to the lipoplexes
causes, in the case of both the ‘pre TAT-lipoplexes’ (pre TAT-
LPX) and the ‘post TAT-lipoplexes’ (post TAT-LPX), a
significant ( p<0.05; ANOVA) increase in particle size and
surface charge. The latter is an indication that cationic TAT
peptides were indeed attached to the surface of the pegylated
lipoplexes. The particle size and surface charge of the 10 mol%
DOTAP lipoplexes could not be determined accurately, due to
large aggregates and/or a too high polydispersity. This is not
surprising as huge amounts of free pDNA were present in the
10 mol% DOTAP lipoplexes (Fig. 2).
3.2. Cytotoxicity
Several groups have reported a significant cytotoxicity of
free TAT peptides [9,39,40]. Therefore, we characterized the
cytotoxicity of our lipoplexes by measuring the mitochondrial
activity. Linking of TAT peptides to the lipoplexes slightly
Fig. 1. Schematic representation of the TAT-modified DOTAP:DOPE:DSPE-PEG2000-MAL lipoplexes.
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which mechanism TATcauses cell toxicity, however, it has been
shown in HeLa cells that the α-helix structure, present in the
TAT AA 37–72 peptide, plays an important role [11].
Furthermore, except for the pre TAT-LPX containing 10 and
30 mol% DOTAP, the cytotoxicity of the lipoplexes slightly
increased when they contain lower amounts of DOTAP and thus
higher amounts of DOPE. DOPE is a fusiogenic lipid that
disrupts endosomal membranes during their acidification [41].
A higher DOPE content in the lipoplexes probably results in anFig. 2. Agarose gelelectrophoresis of unmodified, pre and post TAT-LPX conincreased endosomal breakdown, which, as previously been
suggested for polyethyleneimine [5], may explain the increased
cytotoxicity.
3.3. Transfection capacity of unmodified and TAT-modified
lipoplexes
The transfection efficiency of the unmodified lipoplexes, the
‘pre TAT-LPX’ and the ‘post TAT-LPX’ were subsequently
compared. To correct for the above observed cytotoxicity of thetaining 10, 30 and 50 mol% DOTAP before and after addition of SDS.
Fig. 4. Cytotoxicity of unmodified and TAT-modified lipoplexes containing 10,
30 or 50 mol% DOTAP relatively to untreated cells. Data are shown as mean±
SD with n=3.
Fig. 3. Zeta potential (A) and size (B) measurement of the unmodified and TAT-
modified lipoplexes containing 30 mol% (dark grey) and 50 mol% (light grey)
DOTAP. The size and zeta potential of the 10 mol% DOTAP lipoplexes could
not be measured accurately due to the presence of large aggregates and/or a too
high polydispersity. All data are shown as mean±SD with n=4 for DLS and
n=5 for zetapotential data. The asterisk (*) represents data points that
significantly differ ( p<0.05; ANOVA) from the data of unmodified lipoplexes.
575R.E. Vandenbroucke et al. / Biochimica et Biophysica Acta 1768 (2007) 571–579lipoplexes, the results of the transfection experiments were
expressed relatively to the total cell protein content.
Fig. 5 reveals the following trends. First, the transfection
capacity of the lipoplexes increased with increasing DOTAP
content: the gene expression of the 50 mol% DOTAP lipoplexes
without TAT peptide was 3.3 fold and with TAT peptide 1.4 fold
higher than the gene expression of the corresponding 30 mol%
DOTAP lipoplexes. Second, TAT peptide enhanced the gene
expression of the 30 mol% DOTAP lipoplexes. ‘Post TAT’
modification of these lipoplexes gave the best results and led to
a doubling of the transfection efficacy. This effect of TAT is
slightly smaller than the effect of TAT seen on the gene
expression of the lipoplexes used in the work of Torchilin et al.
[42]. This may be explained by the lower initial gene expression
of the lipoplexes in the latter work, which made it more likely
that TAT could increase their gene expression. Additionally, the
fact that in Torchilin's work a shorter TAT peptide was used
may also explain the slight difference in gene expression. Third,
Fig. 5 shows that the TAT peptide could not further enhance the
gene transfer capacity of the (well transfecting) 50 mol%
DOTAP lipoplexes. The ‘post modification’ of the 30 mol%
DOTAP lipoplexes with TAT gave also slightly higher
transfection efficiencies compared to the ‘pre modification’.
This may indicate that the preceding attachment of TAT to the
liposomes complicated an efficient complexation of the pDNA.
Finally, the unmodified 10 mol% DOTAP lipoplexes did not
transfect the cells, which is explained by their poor DNA
binding capacity (see Fig. 2). Also TAT-modified 10 mol%
lipoplexes showed low transfection efficiency despite the
reduced amount of free DNA caused by electrostatic binding
of the TAT peptides to the free pDNA. However, we
(unpublished data) and others have shown [43,44] that such
TAT/pDNA complexes do not posses significant gene transfer
capacities. Consequently, this explains why addition of TAT
peptides to the 10 mol% DOTAP lipoplexes did not enhance
their gene expression. Considering the low gene expression of
the 10 mol% lipoplexes we decided to exclude them in our
further work.Fig. 5. Transfection efficiency of the unmodified, pre and post TAT-LPX
containing 10 (black), 30 (dark grey) or 50 mol% (light grey) DOTAP. Data are
shown as mean±SD and n=3. The asterisk (*) represents data points that
significantly differ ( p<0.05; ANOVA) from the data of unmodified lipoplexes.
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energy dependent manner and turn up in acidic vesicles
The ability of TAT peptides to enhance the uptake of
liposomes and other types of nanoparticles was demonstrated by
several groups at the beginning of thismillennium [29,30,43,45].
Later on, Torchilin et al. [42] showed that the cellular uptake and
gene expression of lipoplexes was also enhanced when TAT
peptides were coupled to their surface. In all these reports it was
proposed that the TAT-modified particles penetrate the cell
membrane in an energy independent manner. In contrast, Fretz
et al. [31] showed that OVCAR cells internalize TAT peptide
modified liposomes by energy dependent endocytosis. To
determine whether the TAT-modified lipoplexes under investi-
gation in this study follow an energy dependent or independent
pathway, we focused on the cellular uptake of FITC-labeled
lipoplexes at 4 °C and 37 °C by confocal scanning fluorescence
microscope (Fig. 6). To elucidate whether the lipoplexes end-up
in acidic vesicles, the cells were pre-incubated with Lyso-
Tracker® Red, a compound known to localize primarily in the
acidic compartments of cells [46]. The experiments were
performed using living cells, as previous reports have shown
that cell fixationmay lead to an artificial uptake of TAT-modified
proteins [18]. Fig. 6A, B, E and F show that after incubation at
37 °C, both the unmodified and TAT peptidemodified lipoplexes
were rapidly (even within 5 min) taken up by the cells. However,
at 4 °C the uptake was negligible for both types of lipoplexes
(Fig. 6C, D, G and H). In contrast to previous reports this clearly
demonstrates that the uptake of the TAT-modified lipoplexes
occurs, like for unmodified lipoplexes, via an energy-dependent
process. To further confirm the energy dependency of the cellular
uptake of the lipoplexes, we performed transfection experiments
at 4 °C. As expected from the data above, gene expression of
both the TAT-modified and unmodified lipoplexes was reducedFig. 6. Confocal laser scanning microscopy images of FITC-labeled unmodified and
at 37 °C (A, B, E and F) and at 4 °C (C, D, G and H). The red fluorescence in the cells
fluorescent from the lipoplexes with the red fluorescence from the Lysotracker® Re
DOTAP lipoplexes.to about 3% of the gene expression measured at 37 °C (data not
shown).
Both the TAT-modified and the unmodified lipoplexes
appeared in the cells in a punctuated pattern and strongly co-
localized with LysoTracker®, a marker of acidic organelles (Fig.
6A, B, E and F). This implies that the lipoplexes were most
likely internalized via a clathrin-mediated pathway as lyso-
somes are the end point of a clathrin-mediated rather than a lipid
raft-mediated internalization pathway. Additionally, the very
fast internalization observed for the lipoplexes, is also typical
for a clathrin-mediated uptake mechanism [47–49]. To further
strengthen this conclusion we subsequently studied the effect of
specific inhibitors of clathrin- and lipid raft-mediated endocy-
tosis on the cellular uptake and gene expression of the
lipoplexes. The fact that at least a portion of our lipoplexes
turns up in lysosomes may be surprising as they contain DOPE,
a helper lipid that is known to promote the endosomal escape of
DNA and hence to avoid degradation of the pDNA by
lysosomal enzymes [50–52].
3.5. Cholesterol-dependent clathrin-mediated endocytosis is
the productive route for gene expression of TAT-modified and
unmodified lipoplexes
Cells can internalize extracellular material via several
mechanisms. The best characterized is the clathrin-coated
pits pathway, which leads to intracellular vesicles that can
either recycle back to the cell membrane or move, while they
undergo a gradual acidification, along the microtubili to the
perinuclear region [53]. Less defined are the lipid raft-
mediated internalization mechanisms, among which the
caveolae-mediated pathway is the best described (reviewed
by [54]). Lipid rafts are dynamic regions of the plasma
membrane which are enriched in cholesterol, sphingomyelin,TAT-modified lipoplexes (containing 30 mol% DOTAP) incubated with the cells
originates from LysoTracker® Red. Yellow indicates co-localization of the green
d. Scale bar represents 10 μm. Similar results were obtained with the 50 mol%
Fig. 7. Transfection efficiency of the unmodified, pre TAT- and post TAT-LPX
containing 30 mol% (A) or 50 mol% (B) DOTAP in the absence or presence of
uptake inhibitors chlorpromazine and filipin. Data are shown as mean±SD and
n=3.
Fig. 8. Confocal laser scanning microscopy images of Cos-7 cells incubated
with FITC-labeled unmodified and TAT-modified 30 mol% DOTAP lipoplexes
in normal conditions (A and B), in the presence of chlorpromazine (C and D)
and in the presence of filipin (E and F). As marker of acidic organelles,
LysoRed® tracker was used. The left panel (A, C and E) shows the merged
images with the complexes represented as green and the lysosomes as red and
the right panel (B, D, F) shows the co-localization of red and green signals. Scale
bar represents 50 μm. The inserts show, at a higher magnification, the co-
localization of LysoRed® tracker and lipoplexes in one cell.
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proteins. For caveolae-mediated uptake it is known that this
pathway leads to neutral vesicles which stay after their
formation near the cell surface before they are transported
via the Golgi apparatus to the endoplasmatic reticulum. It is
obvious that the distinctive intracellular routing profile and
properties of the vesicles occurring from the different pathways
may either favour or disfavour non-viral gene expression.
Nevertheless, the cellular pathways by which non-viral gene
complexes enter mammalian cells have gained the attention of
only a few groups [48,49,55]. Therefore, elucidating the entry
mechanism is of interest for both the TAT-modified and
unmodified lipoplexes.
To study the role of the clathrin- and lipid raft-mediated
endocytosis in the uptake and gene expression of TAT-modified
and unmodified lipoplexes, we performed transfection experi-
ments in the presence of a specific inhibitor of respectively
clathrin-mediated (i.e. chlorpromazine) [35] and lipid raft-
mediated endocytosis (i.e. filipin III) [36]. Chlorpromazine is an
amphiphilic drug that prevents the recycling of clathrin proteins
from formed endosomes back to the cell membrane and inhibits
in this manner the formation of new clathrin-coated pits. On the
other hand, filipin binds strongly to cholesterol which is
especially present in the lipid raft domains of the cell
membrane, which will prevent lipid raft-mediated endocytosis.However, also other entry pathways may be inhibited as
cholesterol is present all over the cell membrane.
The gene expression of the TAT-modified and unmodified
lipoplexes in the presence of chlorpromazine and filipin is
shown in Fig. 7. Chlorpromazine significantly ( p<0.05;
ANOVA) inhibits the gene expression of the 30 mol% (>86%
inhibition) and the 50 mol% (>92% inhibition) DOTAP
lipoplexes. Surprisingly, also filipin lowered the gene expres-
sion of both the TAT-modified and unmodified lipoplexes
significantly ( p<0.05; ANOVA): the inhibition ranged between
46% (for the unmodified lipoplexes) and 66% (for the TAT-
modified lipoplexes). The effect of filipin on the gene
expression was significant lower ( p<0.05; ANOVA) than the
effect of chlorpromazine. In the light of the clear indications for
a clathrin-mediated uptake mechanism of our lipoplexes (i.e.
fast internalization and co-localization with acidic organelles),
we suspect that the effect of filipin is due to its limited
selectivity. Indeed, as cholesterol is required for the formation
of curved coated pits [56,57] the binding of filipin to cholesterol
might consequently also inhibit clathrin-mediated endocytosis.
This hypothesis is in agreement with the work of Zuhorn et al.
[49] who showed that depletion of cell membrane cholesterol by
methyl-β-cyclodextrin, a compound previously proposed to
selectively inhibit caveolae-mediated endocytosis [58,59],
strongly inhibited cholesterol-dependent clathrin-mediated
578 R.E. Vandenbroucke et al. / Biochimica et Biophysica Acta 1768 (2007) 571–579endocytosis of lipoplexes by Cos-7 cells. Therefore, we
speculate here that our lipoplexes are internalized via
cholesterol-dependent clathrin-mediated endocytosis and that
this entry mechanism is also sensitive to filipin. However, we
have to remark that we cannot totally exclude from our data that
a small portion of the lipoplexes are also taken up via caveolae-
mediated endocytosis.
It has been shown that the entry mechanism may depend on
the size of the nanoparticles. Indeed, polystyrene nanoparticles
with a diameter less than 200 nm were exclusively internalized
via clathrin-coated pits, whereas those of 500 nm entered the
cells via caveolae [47]. The average diameter of our lipoplexes,
as determined by DLS, was around 300 nm. However, the size
distribution of these lipoplexes typically ranged between 100
and 350 nm, with more than 70% of the lipoplexes having a
diameter smaller than 200 nm. Therefore, from the size of the
lipoplexes a clathrin-mediated endocytosis pathway and to a
lesser extend a caveolae-mediated pathway could be expected.
Finally, fluorescence confocal microscopy experiments
showed a nice correlation between the decrease in gene
expression caused by chlorpromazine or filipin and the amount
of internalized lipoplexes in the presence of the respective
uptake inhibitors (Fig. 8). In normal conditions (Fig. 8A and B),
the 30 mol% lipoplexes clearly co-localize with the lysosomes,
while the presence of chlorpromazine (Fig. 8C and D) almost
completely blocks the co-localization. In contrast, filipin (Fig.
8E and F) partially inhibits the uptake of the complexes. Similar
results were obtained with the 50 mol% lipoplexes.
In conclusion, our study shows that the gene transfer of
lipoplexes containing 30 mol% DOTAP can be enhanced by
coupling TAT peptides to their surface. Post modification of
pre-formed lipoplexes with TAT gives the best results. In
contrast, addition of TAT to lipoplexes containing 50 mol%
DOTAP does not improve their gene transfer. In contrast to
previous reports [30] we clearly demonstrate that the uptake of
both TAT-modified and unmodified lipoplexes is energy
dependent. Furthermore, by using cellular uptake inhibitors
we suppose that the TAT-modified and unmodified lipoplexes
enter the cytoplasm mainly via cholesterol-dependent clathrin-
mediated endocytosis, a pathway previously postulated by
Zuhorn et al. [49] for the cellular uptake of cationic lipoplexes.
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